|
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Angle; AxImmune; Bayer; Janssen Oncology; Pfizer; ScreenCell |
Consulting or Advisory Role - Angle; AxImmune; Bayer; Pfizer; Sanador |
Research Funding - Genentech; Janssen Research & Development (Inst); Prostate Cancer Foundation |
Patents, Royalties, Other Intellectual Property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER |
Travel, Accommodations, Expenses - American Austrian Open Medical Institute; Angle; Bayer; Cambridge Healthtech Institute; Prostate Cancer Foundation; ScreenCell; Stop Cancer |
| |
William Jeffery Edenfield |
Consulting or Advisory Role - Chimerix |
| |
|
Honoraria - Clovis Oncology |
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen |
Research Funding - Abbvie (Inst); Amgen (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst) |
Travel, Accommodations, Expenses - Xynomic Pharma |
| |
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma |
Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst) |
Expert Testimony - Celgene; sanofi |
| |
|
Stock and Other Ownership Interests - Abbvie; Cardinal Health; GlaxoSmithKline; Lilly; PSMA Therapeutics; United Health Group; Varian Medical Systems |
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Myovant Sciences; Myriad Genetics; Novartis; Novartis; Noxopharm; Pfizer; Progenics; Sanofi |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck (Inst); Sanofi (Inst); SOTIO |
Expert Testimony - Sanofi |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Noxopharm; Roche; Seagen |
Speakers' Bureau - Exelixis; Prometheus |
Research Funding - Bayer; Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Incyte; Janssen; Merck; Pharmacyclics; QED Therapeutics; Seagen |
Research Funding - Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Research Funding - Genentech (Inst); Merck (Inst) |
| |
|
Consulting or Advisory Role - Abbvie; Amgen; AZTherapies; Bristol-Myers Squibb; Celgene; CTI; Janssen Oncology; McGivney Global Advisors |
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
Honoraria - Dendreon; Janssen Oncology |
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi |
Speakers' Bureau - Bayer; Dendreon |
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst) |
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech |
| |
|
Employment - Connected Medical Solutions (I) |
Leadership - Connected Medical Solutions (I) |
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems |
Consulting or Advisory Role - Imagion Biosystems |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer |
| |
|
Honoraria - Astellas Pharma; Ipsen; Novartis |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme (Inst); Pfizer (Inst) |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Pfizer |
| |
|
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst) |
Other Relationship - Pfizer |
| |
|
|
|
| |
|
|
Stock and Other Ownership Interests - Amgen; Johnson & Johnson |
| |
|
|
Stock and Other Ownership Interests - Amgen |